TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 4, Issue 3, 2017
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
COMPARATIVE EFFICACY OF FLUCONAZOLE AND GRISEOFULVIN IN THE TREATMENT OF CHRONIC DERMATOPHYTOSIS: A RANDOMIZED CONTROLLED TRIAL
Author
V.T. SriRam1, Nageswara Rao D
Email
drpebyreddy@gmail.com
keyword
Chronic Dermatophytosis, Fluconazole, Griseofulvin, Antifungal therapy
Abstract
Fungal diseases affect nearly a billion people globally, with serious infections significantly impacting quality of life and contributing to over 1.6 million deaths annually. Dermatophytosis, a superficial fungal infection affecting the hair, skin, and nails, is particularly prevalent in India. This randomized controlled trial aimed to compare the efficacy of two antifunga treatments, fluconazole and griseofulvin, in managing chronic dermatophytosis. Conducted at Sri Lakshmi Narayana Institute of Medical Sciences, Pondicherry, India, the study included 100 patients randomized into two groups. Group A received fluconazole (150 mg) thrice weekly, while Group B received griseofulvin (500 mg) twice daily, both for six weeks The primary outcome was the reduction in KOH positivity, a marker of fungal presence. Results showed that fluconazole was more effective, reducing KOH positivity from 70% before treatment to 10% at six weeks, compared to a reduction from 80% to 30% in the griseofulvin group. Additionally, steroid use was prevalent, with 70% of fluconazole and 80% o griseofulvin patients using steroids, which may have influenced treatment outcomes. The study concluded that fluconazole offers superior efficacy in reducing fungal presence in chronic dermatophytosis, although the impact of steroid use warrants further investigation. These findings suggest that fluconazole should be considered as a first-line treatment option, with careful management of concomitant steroid use to optimize outcomes
Download Broucher
Back to Top >>>>